RedHill Biopharma Ltd.

RDHL • Drug Manufacturers - Specialty & Generic

$0.72

▲ +0.01 (+1.63%)

Current price

EarningsLatest report: Dec 31, 2025

WEAK PROFILEWeakConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.

Market Cap

$1.31M

Growth

—

Cash Flow

0/5

Trend

Negative

Evidence

Manageable debt level · 0.25Weak liquidity · 0.34Negative growth trendWeak profitability

Financial data as of: Dec 31, 2025, 12:00 AM UTCLast earnings update: Dec 31, 2025, 12:00 AM UTCLast profile update: Sep 2, 2026, 12:17 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$0.72

Change1.63%

Shares Out1.80M

Market Cap$1.31M

Enterprise Value$-2.66M

52W Range0.57 - 2.79

Beta4.90

P/E-0.14

P/S0.14

P/B0.31

P/FCF-0.16

EV/Sales-0.28

Price$0.72

Change1.63%

Shares Out1.80M

Market Cap$1.31M

Enterprise Value$-2.66M

52W Range0.57 - 2.79

Beta4.90

P/E-0.14

P/S0.14

P/B0.31

P/FCF-0.16

EV/Sales-0.28

EV/EBITDA0.34

EV/FCF0.32

Earnings Yield-713.04%

FCF Yield-628.67%

Dividend Yield0.00%

Gross Margin100.00%

Oper. Margin-27.65%

Profit Margin-150.00%

Debt/Eq0.25

Current Ratio0.34

Quick Ratio0.34

Volume3.69M

Avg Volume163.55K

EPS Surprise-170.00

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

22/100

Financial Strength

Debt, cash, stability

39/100

Growth Potential

Revenue and expansion

20/100

Price Attractiveness

Cheap or expensive today

58/100

Why this score▼

Manageable debt level · 0.25Weak liquidity · 0.34Negative growth trendWeak profitability

Analyst view

Analyst sentiment and price target

RDHL

Analyst sentiment

Based on 10 analyst votes · 2026-09-05

100/100

Bullish

Hold

Bearish

Company Overview

IPO: 1/7/2013

Industry: Drug Manufacturers - Specialty & Generic

P/B i: 0.31

Debt / Equity i: 0.25

Operating Margin: -2765.38%

Net Margin: -150.00%

ROE i: -

ROIC: -

Financial Health

Score8 / 20

Debt / Equity: 0.25

Current Ratio: 0.34

Quick Ratio: 0.34

Status: Moderate

Warnings

Weak Liquidity
Weak quick ratio

Insider Transactions

Recent executive and insider activity

⚠ 2 high-volume insider sells detected

Raday Gilead

Transaction: 07/10/2026

BUY

Change

+28,150,000

Price

Not reported

Filing

07/13/2026

Type

BUY

Raday Gilead

Transaction: 07/10/2026

SELL

Change

-14,130,000

Price

$0.00

Filing

07/13/2026

Type

SELL

Raday Gilead

Transaction: 04/06/2026

BUY

Change

+30,780,000

Price

Not reported

Filing

04/22/2026

Type

BUY

Insider	Type	Change	Price	Transaction	Filing
Raday Gilead	BUY	+28,150,000	Not reported	07/10/2026	07/13/2026
Raday Gilead	SELL	-14,130,000	$0.00	07/10/2026	07/13/2026
Raday Gilead	BUY	+30,780,000	Not reported	04/06/2026	04/22/2026
Raday Gilead	SELL	-15,740,000	$0.00	04/06/2026	04/22/2026
Tsimchi Ofer	OTHER	+180,000	Not reported	03/18/2026	03/19/2026
Tsimchi Ofer	OTHER	+36,440,000	Not reported	03/18/2026	03/19/2026
Tsimchi Ofer	OTHER	0	Not reported	03/18/2026	03/19/2026
Ben-Asher Dror	OTHER	+1,100,000	Not reported	03/18/2026	03/18/2026
Ben-Asher Dror	OTHER	+103,360,000	Not reported	03/18/2026	03/18/2026
Ben-Asher Dror	OTHER	0	Not reported	03/18/2026	03/18/2026
Cabilly Shmuel	OTHER	+180,000	Not reported	03/18/2026	03/18/2026
Cabilly Shmuel	OTHER	+30,630,000	Not reported	03/18/2026	03/18/2026
Cabilly Shmuel	OTHER	0	Not reported	03/18/2026	03/18/2026
Frish Adi	OTHER	+750,000	Not reported	03/18/2026	03/18/2026
Frish Adi	OTHER	+62,800,000	Not reported	03/18/2026	03/18/2026
Frish Adi	OTHER	0	Not reported	03/18/2026	03/18/2026
Goldberg Guy Joel	OTHER	+600,000	Not reported	03/18/2026	03/18/2026
Goldberg Guy Joel	OTHER	+555,310,000	Not reported	03/18/2026	03/18/2026
Goldberg Guy Joel	OTHER	0	Not reported	03/18/2026	03/18/2026
Ingber Razi	OTHER	+230,000	Not reported	03/18/2026	03/18/2026

About the Company

RedHill Biopharma Ltd.

RedHill Biopharma Ltd. is a specialized pharmaceutical firm concentrating its efforts mainly on therapies for digestive tract conditions and various infections. The company markets several gastrointestinal medications: Movantik, which addresses opioid-induced constipation in adults experiencing chronic non-cancer pain; Talicia, used to treat Helicobacter pylori infections in adult patients; and Aemcolo, prescribed for adults suffering from travelers' diarrhea. Its robust late-stage clinical pipeline features several promising investigational compounds. RHB-204 is currently in Phase 3 for pulmonary nontuberculous mycobacteria infections. Opaganib (Yeliva), an SK2 selective inhibitor, has completed Phase 2 for severe SARS-CoV-2 related COVID-19 pneumonia, is in Phase 2 for advanced unresectable cholangiocarcinoma, and is also being investigated in a researcher-sponsored Phase 2 study for prostate cancer. RHB-107 is progressing through Phase 2/3 trials for COVID-19 outpatients, is undergoing preclinical evaluation for advanced unresectable cholangiocarcinoma, and has successfully concluded Phase 2 studies for gastrointestinal and other solid tumors. Furthermore, RHB-104 is in Phase 3 development for Crohn's disease. RHB-102 (Bekinda) is also in Phase 3 for acute gastroenteritis and gastritis, following its successful completion of Phase 2 for irritable bowel syndrome with diarrhea. Lastly, RHB-106, an encapsulated formulation designed for bowel preparation, is preparing to commence Phase 2/3 clinical studies. Established in 2009, RedHill Biopharma Ltd. maintains its headquarters in Tel Aviv, Israel.

Source - link

Peers

AKAN BGMS BNBX CNSP FLGC GCTK IMCC JAGX MSPR SXTP

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq®

Together with the previously announced Talicia® strategic divestiture, the acquisition from Ferring of commercialization rights to two larger, proprietary, established gastrointestinal (GI) FDA-approved drugs that together generated approximately $37.5 million in 2025 net sales, completes a major strategic repositioning of RedHill's commercial GI business The divestiture of Talicia and the acquisition of the new GI products from Ferring create a catalyst for commercial growth through a materially larger GI business under RedHill's control, with a significantly stronger liquidity position and provides additional growth and expansion opportunities Under the terms of the agreement, RedHill obtained the exclusive commercialization rights for an upfront payment to Ferring of $12 million plus potential future milestones and tiered royalties. The $12 million upfront payment is fully funded through the previously announced $18 million Talicia divestment, with RedHill securing exclusive global and U.S. commercialization rights to Ferring's Rebyota® and Clenpiq®, respectively - two synergistic, revenue-generating, FDA-approved GI drugs Rebyota is a proprietary, first and only single-dose FDA-approved Fecal Microbiota Transplant (FMT for prevention of recurrent C.

PRNewsWire

RedHill Divests Talicia® to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities

Executes a major step in RedHill's strategic roadmap to fundamentally reposition the Company's commercial business toward new and larger product opportunities, revenue growth and an accelerated path toward operational profitability -- Realizes substantial value from RedHill's 70% stake in Talicia, currently held within a shared ownership and economic structure, while immediately creating a stronger liquidity position and fully funding the next major steps in RedHill's transformational commercial expansion -- Under the terms of the agreement, Apotex will pay RedHill an upfront payment of $18 million plus up to an additional $35 million in potential worldwide net sales milestone payments RALEIGH, N.C. and TEL AVIV, Israel, Aug. 31, 2026 /PRNewswire/ -- RedHill Biopharma Ltd.

PRNewsWire

Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development

The number of confirmed Ebola cases and deaths has increased substantially to 3221 cases and 1407 deaths -- Finalization of development next steps and potential partnership discussions ongoing, including with the Emergency Task Force expert group of the African Medicines Agency, the Ugandan Ministry of Health and Mbarara University of Science and Technology (MUST), alongside liaison with the Democratic Republic of Congo (DRC) Scientific Advisory Committee -- Professor Pauline Byakika-Kibwika, Vice Chancellor, MUST: "There is an urgent need for additional therapeutic options, and with an oral formulation, ease of administration, human safety database and supportive data, host-directed antiviral opaganib warrants immediate evaluation as a potential treatment candidate for Bundibugyo ebolavirus (BDBV)" -- Development of opaganib for Ebola is supported by preclinical and clinical safety and efficacy data from multiple studies, including in combination with direct acting antiviral Veklury® (remdesivir, Gilead Sciences) TEL AVIV, Israel and RALEIGH, N.C., July 28, 2026 /PRNewswire/ -- RedHill Biopharma Ltd.

PRNewsWire

RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement

$6 million upfront with up to approximately $13.4 million of potential aggregate gross proceeds upon the exercise in full of warrants TEL AVIV, Israel and RALEIGH, N.C., June 22, 2026 /PRNewswire/ -- RedHill Biopharma Ltd.

PRNewsWire

RedHill Biopharma Announces Up To $19.4 Million Private Placement

$6 million upfront with up to approximately $13.4 million of potential aggregate gross proceeds upon the exercise in full of warrants TEL AVIV, Israel & RALEIGH, N.C., June 18, 2026 /PRNewswire/ -- RedHill Biopharma Ltd.

PRNewsWire

Earnings Surprises

Period	Estimate	Actual	Surprise
2024-08-29	-30	-200	-170
2024-02-12	-0.03	-0.2	-0.17
2022-11-07	-0.3	-2	-1.7
2022-06-23	-4	-3	1
2022-03-17	-4	-5	-1
2021-11-30	-4.8	-4.6	0.2
2021-08-26	-4	-6.2	-2.2
2021-05-27	-4.6	-5.3	-0.7
2021-03-18	-4.5	-7	-2.5
2020-11-12	-2.2	-5	-2.8
2020-08-13	-1.4	-4.5	-3.1
2020-05-27	-3.8	-4.9	-1.1